<DOC>
	<DOC>NCT00260208</DOC>
	<brief_summary>Following a transplant for hepatitis C cirrhosis, the infection comes back in 70-90% of cases and over time causes fibrosis and eventually cirrhosis of the new liver. The aim of this study was to see if the frequency of liver fibrosis was different with cyclosporine microemulsion than tacrolimus</brief_summary>
	<brief_title>Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion criteria Reason for transplant is endstage liver disease due to hepatitis C cirrhosis Patients receiving a first liver transplant from a deceased or living donor Patients in whom biopsies will be possible Exclusion criteria Recipients of a liver from an hepatitis C virus positive (HCV+), human immunodeficiency virus positive (HIV+) or hepatitis B virus positive (HBV+) donor Patients with any severe coexisting disease or suffering any unstable medical condition or coinfected with HBV or HIV Patients with coexisting alcoholic disease who have not been abstinent for at least 6 months Transplanted for liver cancer exceeding a predefined size Pregnant or nursing women Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Liver transplant, adults, hepatitis C, liver fibrosis, cyclosporine microemulsion, tacrolimus</keyword>
</DOC>